These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37245859)

  • 21. Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease.
    Alvares D; Hoffman S; Stankovic B; Adeli K
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Mar; 1864(3):326-334. PubMed ID: 30578967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease.
    Chikamatsu M; Watanabe H; Shintani Y; Murata R; Miyahisa M; Nishinoiri A; Imafuku T; Takano M; Arimura N; Yamada K; Kamimura M; Mukai B; Satoh T; Maeda H; Maruyama T
    J Control Release; 2023 Mar; 355():42-53. PubMed ID: 36690035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploiting the biological effect exerted by lipid nanocapsules in non-alcoholic fatty liver disease.
    Domingues I; Michalowski CB; Marotti V; Zhang W; Van Hul M; Cani PD; Leclercq IA; Beloqui A
    J Control Release; 2023 Apr; 356():542-553. PubMed ID: 36907563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Incretin as a Novel Treatment Strategy for NAFLD/NASH].
    Takeda Y; Ikeda R; Kondo T
    Yakugaku Zasshi; 2016; 136(4):573-7. PubMed ID: 27040341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.
    Liu Y; Wei R; Hong TP
    World J Gastroenterol; 2014 Jul; 20(27):9090-7. PubMed ID: 25083081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes.
    Barb D; Bril F; Kalavalapalli S; Cusi K
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3327-3336. PubMed ID: 30848827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis.
    Xue H; Xing HJ; Wang B; Fu C; Zhang YS; Qiao X; Guo C; Zhang XL; Hu B; Zhao X; Deng LJ; Zhu XC; Zhang Y; Liu YF
    Drug Des Devel Ther; 2023; 17():1417-1432. PubMed ID: 37197367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.
    Alisi A; Ceccarelli S; Panera N; Prono F; Petrini S; De Stefanis C; Pezzullo M; Tozzi A; Villani A; Bedogni G; Nobili V
    PLoS One; 2013; 8(6):e67160. PubMed ID: 23840612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge.
    Liu D; Pang J; Shao W; Gu J; Zeng Y; He HH; Ling W; Qian X; Jin T
    Hepatology; 2021 Oct; 74(4):2154-2169. PubMed ID: 33851458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1.
    Yin YH; Sang LX; Chang B
    World J Gastroenterol; 2023 Dec; 29(48):6235-6238. PubMed ID: 38186863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome.
    Kim ER; Park JS; Kim JH; Oh JY; Oh IJ; Choi DH; Lee YS; Park IS; Kim S; Lee DH; Cheon JH; Bae JW; Lee M; Cho JW; An IB; Nam EJ; Yang SI; Lee MS; Bae SH; Lee YH
    Hepatology; 2022 Jun; 75(6):1523-1538. PubMed ID: 34773257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
    Liu J; Xu Y; Hu Y; Wang G
    Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
    Doumas M; Imprialos K; Stavropoulos K; Athyros VG
    Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
    Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of GLP-1 and Glucagon Receptors Regulates Bile Homeostasis Independent of Thyroid Hormone.
    Patel VJ; Joharapurkar AA; Kshirsagar SG; Sutariya BK; Patel MS; Bahekar RH; Jain MR
    Curr Mol Pharmacol; 2019; 12(2):139-146. PubMed ID: 30747091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice.
    Finn PD; Rodriguez D; Kohler J; Jiang Z; Wan S; Blanco E; King AJ; Chen T; Bell N; Dragoli D; Jacobs JW; Jain R; Leadbetter M; Siegel M; Carreras CW; Koo-McCoy S; Shaw K; Le C; Vanegas S; Hsu IH; Kozuka K; Okamoto K; Caldwell JS; Lewis JG
    Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G412-G424. PubMed ID: 30605011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.
    Barritt AS; Marshman E; Noureddin M
    Aliment Pharmacol Ther; 2022 Apr; 55(8):944-959. PubMed ID: 35266164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic effect of long-acting FGF21 with controlled site-specific modification on nonalcoholic steatohepatitis.
    Qi J; Guo Z; Zhu S; Jiang X; Wu Y; Chen Y; Hu F; Xiong J; Wu Y; Ye X; Liang X
    Int J Biol Macromol; 2024 Mar; 261(Pt 1):129797. PubMed ID: 38290625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.